Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: Implications for colon cancer prevention

International Journal of Oncology

Volumn 35, Issue 5, 2009, Pages 1037-1043

  Guruswamy, Suresh ^a   Rao, Chinthalapally V ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Caveolin 1; Chemoprevention; Colon cancer; Cyclooxygenase 2; Hydroxy methyl glutaryl CoA; Reductase; Tumor suppressor proteins

Indexed keywords

CAVEOLIN 1; CELECOXIB; MEVINOLIN; PROTEIN KINASE B;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HCT116; CELL SURVIVAL; CELL VIABILITY; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CAVEOLIN 1; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG SYNERGISM; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LOVASTATIN; PYRAZOLES; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 70449574594     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000418     Document Type: Article

References (40)

1. American Cancer Society: Colorectal Cancer Facts. Atlanta, GA, USA, 2007.
2. Smith R, von Eschenbach A and Wender R: American Cancer Society Guidlines for early detection of cancer: Update of early detection guidlines for prostate, colorectal and endometrial cancers. CA Cancer J Clin 51: 38-75, 2001. (Pubitemid 32166445)
3. Rao CV, Indranie C, Simi B, Manning PT, Connor JR and Reddy BS: Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 62: 165-170, 2002. (Pubitemid 34074001)
4. Swamy MV, Cooma I, Patlolla JM, Simi B, Reddy BS and Rao CV: Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: novel strategies for colon cancer prevention and treatment. Mol Cancer Ther 2: 215-221, 2004. (Pubitemid 39193696)
5. Swamy MV, Cooma I, Reddy BS and Rao CV: Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens. Int J Oncol 20: 753-759, 2002.
6. Min mice. Cancer Res 66: 7370-7377, 2006.
7. Reddy BS, Wang CX, Kong AN, Khor TO, Zheng X, Steele VE, Kopelovich L and Rao CV: Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 66: 4542-4546, 2006.
8. Anderson RGW: Caveolae: Where incoming and outgoing messengers meet. Proc Natl Acad Sci USA 90: 10909-10913, 1993. (Pubitemid 23354338)
9. Anderson RGW: The caveolae membrane system. Annu Rev Biochem 67: 199-225, 1998.
10. Li SW, Okamoto T, Chun MY, Sargiacomo M, Casanova JE, Hansen SH, Nishimoto I and Lisanti MP: Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J Biol Chem 270: 15693-15701, 1995.
11. Huang C, Hepler JR, Chen LT, Gilman AG, Anderson RG and Mumby SM: Organization of G proteins and adenylyl cyclase at the plasma membrane. Mol Biol Cell 8: 2365-2378, 1997. (Pubitemid 27528207)
12. Patlolla JM, Swamy MV, Raju J and Rao CV: Overexpression of caveolin-1 in experimental colon adenocarcinomas and human colon cancer cell lines. Oncol Rep 11: 957-963, 2004.
13. Simons K and Ikonen E: Functional rafts in cell membranes. Nature 387: 569-572, 1997.
14. Simons K and Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 1: 31-39, 2001.
15. Coimbra A and Lopes-Vaz A: The presence of lipid droplets and the absence of stable sudanophilia in osmium-fixed human leukocytes. J Histochem Cytochem 19: 551-557, 1971.
16. Weinstein J: Synovial fluid leukocytosis associated with intracellular lipid inclusions. Arch Intern Med 140: 560-561, 1980.
17. Martin S and Parton RG: Lipid droplets: a unified view of a dynamic organelle. Nat Rev Mol Cell Biol 7: 373-378, 2006.
18. Fine SW, Lisanti MP, Galbiati F and Li M: Elevated expression of caveolin-1 in adenocarcinoma of the colon. Am J Clin Pathol 15: 719-724, 2001. (Pubitemid 33051539)
19. Yang G, Truong LD, Wheeler TM and Thompson TC: Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 59: 5719-5723, 1999.
20. Nagajyothi F, Desruisseaux M, Bouzahzah B, et al: Cyclin and caveolin expression in an acute model of murine Chagasic myocarditis. Cell Cycle 5: 107-112, 2006.
21. Li L, Ren CH, Tahir SA, Ren C and Thompson TC: Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 24: 9389-9404, 2003. (Pubitemid 37499824)
22. Bellacosa A, Kumar CC, Di Cristofano A and Testa JR: Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94: 29-86, 2005. (Pubitemid 41202364)
23. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997. (Pubitemid 27456390)
24. Kortylewski M, Feld F, Krüger KD, et al: Akt modulates STAT3-mediated gene expression through a FKHR (FOXO1a)- dependent mechanism. J Biol Chem 278: 5242-5249, 2003. (Pubitemid 36801037)
25. Zhuang ZY, Xu H, Clapham DE and Ji RR: Phosphatidylinositol 3-kinase activates ER in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization. J Neurosci 24: 8300-8309, 2004. (Pubitemid 39280809)
26. Sweatt JD: Mitogen-activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol 14: 311-317, 2004. (Pubitemid 38759861)
27. Wada T and Penninger JM: Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23: 2838-2849, 2004. (Pubitemid 38638846)
28. Kuroki M and O'Flaherty JT: Extracellular signal-regulated protein kinase (ERK)-dependent and ERK-independent pathways target STAT3 on serine-727 in human neutrophils stimulated by chemotactic factors and cytokines. Biochem J 341: 691-696, 1999. (Pubitemid 29389200)
29. Vanhaesebroeck B, Leevers SJ, Ahmadi K, et al: Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem70: 535-602, 2001. (Pubitemid 32662219)
30. Fatrai S, Elghazi L, Balcazar N, Cras-Meneur C, Krits I, Kiyokawa H and Berna Mizrachi E: Akt induces beta-cell proliferation by regulating cyclin D1, cyclin D2, and p21 levels and cyclin-dependent kinase-4 activity. Diabetes 55: 318-325, 2006. (Pubitemid 43343259)
31. Quelle DE, Ashmun RA, Shurtleff SA, Kato JY, Bar-Sagi D, Roussel MF and Sherr CJ: Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 7: 1559-1571, 1993. (Pubitemid 23234349)
32. Bock JM, Menon SG, Sinclair LL, Bedford NS, Goswami PC, Domann FE and Trask DK: Celecoxib toxicity is cell cycle phase specific. Cancer Res 67: 3801-3808, 2007.
33. Dvorak AM, Morgan E, Tzizik DM and Weller PF: Prostaglandin endoperoxide synthase (cyclooxygenase): ultrastructural localization to nonmembrane-bound cytoplasmic lipid bodies in human eosinophils and murine 3T3 fibroblasts. Int Arch Allergy Immunol 105: 245-250, 1994. (Pubitemid 24317996)
34. Bozza PT, Yu W, Penrose JF, Morgan ES, Dvorak AM and Weller PF: Eosinophil lipid bodies: specific, inducible intracellular sites for enhanced eicosanoid formation. J Exp Med 186: 909-920, 1997. (Pubitemid 27407352)
35. Weller PF, Monahan-Earley RA, Dvorak HF and Dvorak AM: Cytoplasmic lipid bodies of human eosinophils: subcellular isolation and analysis of arachidonate incorporation. Am J Pathol 138: 141-148, 1991.
36. Bozza PT, Payne JL, Morham SG, Langenbach R, Smithies O and Weller PF: Leukocyte lipid body formation and eicosanoid generation: cyclooxygenase- independent inhibition by aspirin. Proc Natl Acad Sci USA 93: 11091-11096, 1996. (Pubitemid 26333123)
37. Serhan CN: Signalling the fat controller. Nature 384: 23-24, 1996.
38. Cohen AW, Razani B, Schubert W, et al: Role of caveolin-1 in the modulation of lipolysis and lipid droplet formation. Diabetes 53: 1261-1270, 2004. (Pubitemid 38569012)
39. Fujimoto T, Kogo H, Ishiguro K, Tauchi K and Nomura R: Caveolin-2 is targeted to lipid droplets, a new 'membrane domain' in the cell. J Cell Biol 152: 1079-1085, 2001.
40. Razani B, Combs TP, Wang XB, et al: Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem 277: 8635-8647, 2002. (Pubitemid 34968330)